
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY AND INSTRUMENT
I Background Information:
A 510(k) Number
K240998
B Applicant
Radiometer Medicals ApS
C Proprietary and Established Names
ABL90 FLEX PLUS System
D Regulatory Information
Product Regulation
Classification Panel
Code(s) Section
21 CFR 862.1120 -
Blood Gases (PCO2, CH - Clinical
CHL Class II
PO2) and Blood pH Chemistry
Test Systems
21 CFR 864.5620 –
GKR Class II Automated HE - Hematology
Hemoglobin System
21 CFR 864.7425 –
GHS Class II Carboxyhemoglobin HE - Hematology
Assay
II Submission/Device Overview:
A Purpose for Submission:
Modification to a previously cleared device.
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
www.fda.gov

[Table 1 on page 1]
	Product		Classification		Regulation		Panel
	Code(s)				Section		
CHL			Class II	21 CFR 862.1120 -
Blood Gases (PCO2,
PO2) and Blood pH
Test Systems			CH - Clinical
Chemistry
GKR			Class II	21 CFR 864.5620 –
Automated
Hemoglobin System			HE - Hematology
GHS			Class II	21 CFR 864.7425 –
Carboxyhemoglobin
Assay			HE - Hematology

--- Page 2 ---
B Measurand:
1. pH (acidity)
2. pO2 (partial pressure of oxygen)
3. sO2 (oxygen saturation)
4. ctHB (total hemoglobin concentration)
5. FO2Hb (Oxyhemoglobin as a fraction of total hemoglobin))
6. FCOHb (Carboxyhemoglobin)
7. FMetHb (Methemoglobin)
8. FHHb (fraction of total hemoglobin)
C Type of Test:
Quantitative - Sensors using Potentiometry for pH measurement; Spectrophotometry for the
measurement of sO2, ctHb, FO2Hb, FCOHb, FMetHb, and FHHb; and an Optical System for
pO2 measurement.
III Intended Use/Indications for Use:
A Intended Use(s):
See Indications for Use below.
B Indication(s) for Use:
The ABL90 FLEX PLUS System is an in vitro diagnostic, portable, automated analyzer that
quantitatively measures pH, blood gas (pO2), Oximetry (sO2, ctHb, FO2Hb, FCOHb, FMetHb,
and FHHb), in heparinized arterial and venous whole blood.
The ABL90 FLEX PLUS System is intended for use by trained technologists, nurses, physicians
and therapists. It is intended for use in a laboratory environment, near patient, or point-of-care
setting.
These tests are only performed under a physician's order.
pH and pO2: pH and pO2 measurements are used in the diagnosis and treatment of life-
threatening acid-base disturbances.
sO2: Oxygen saturation, more specifically the ratio between the concentration of oxyhemoglobin
and oxyhemoglobin plus reduced hemoglobin.
ctHb (Total Hemoglobin): Total hemoglobin measurements are used to measure the hemoglobin
content of whole blood for the detection of anemia.
FO2Hb: Oxyhemoglobin as a fraction of total hemoglobin.
FCOHb: Carboxyhemoglobin measurements are used to determine the carboxyhemoglobin
content of human blood as an aid in the diagnosis of carbon monoxide poisoning.
FMetHb: Methemoglobin as a fraction of total hemoglobin.
K240998 - Page 2 of 20

--- Page 3 ---
FHHb: Reduced hemoglobin as a fraction of total hemoglobin..
C Special Conditions for Use Statement(s):
Rx - For Prescription Use Only
D Special Instrument Requirements:
ABL90 FLEX PLUS System
IV Device/System Characteristics:
A Device Description:
The ABL90 FLEX PLUS System consists of the ABL90 FLEX PLUS analyzer, sensor cassette
(SC) and solution pack (SP) consumables, and related accessories for the analyzer. The ABL90
FLEX PLUS is a portable, automated system intended for in vitro testing of samples of balanced
heparinized whole blood for the parameters pH, pO2, pCO2 and co-oximetry parameters (total
hemoglobin, oxygen saturation, and the hemoglobin fractions FO2Hb, FCOHb, FMetHb, FHHb
and FHbF). The ABL90 FLEX PLUS System has an automated sample inlet mechanism, which
can collect the blood through two different measuring modes: the S65 syringe mode and the
SP65 short probe mode.
B Principle of Operation:
There are three different measuring principles employed by the ABL90 FLEX PLUS System:
Potentiometry, optical (phosphorescence), and spectrophotometry.
• Potentiometry: The potential of an electrode chain is measured by a voltmeter and related
to the concentration of the sample (the Nernst equation). The potentiometric measuring
principle is applied in the pH and pCO2 sensors.
• Optical pO2: The optical system for pO2 is based on the ability of O2 to reduce the
intensity and time constant of the phosphorescence from a phosphorescent dye that is in
contact with the sample. This measuring principle is applied in the pO2 sensor.
• Spectrophotometry: Light passes through a cuvette that contains a hemolyzed blood
sample. The absorption spectrum is used to calculate oximetry parameters. This
measuring principle is used for ctHb, sO2, FO2Hb, FCOHb, FHHb, and FMetHb.
C Instrument Description Information:
1. Instrument Name:
ABL90 FLEX PLUS System
K240998 - Page 3 of 20

--- Page 4 ---
2. Specimen Identification:
The ABL90 FLEX PLUS System has a built-in barcode reader which can scan the barcode
on the samples from the patient. The sample identifying barcode can also be entered
manually.
3. Specimen Sampling and Handling:
The ABL90 FLEX PLUS System is designed for use with undiluted balanced heparinized
human arterial and venous whole blood. Whole blood from arterial or venous specimens can
be obtained by needle puncture or via an in-line catheter. Sample volume is 65 μL. The
analyzer can aspirate blood samples from different sampling devices, e.g., syringes and test
tubes. Regardless of sampling device, the analyzer will automatically aspirate the required
volume of the sample and draw it into the closed fluid transport system within the system.
4. Calibration:
The ABL90 FLEX PLUS System calibrates most parameters automatically by use of the
calibration solutions in the Solution Pack and by use of atmospheric air for the pO2 sensor.
5. Quality Control:
The analyzer automatically performs quality control checks by measurements on the quality
control solutions included in the Solution Pack. The default setting is one quality control
measurement every 8 hours. Unscheduled QC measurements can also be performed by the
user. Labeling instructs users to follow local, state, and federal guidelines for quality control
and calibration verification.
V Substantial Equivalence Information:
A Predicate Device Name(s):
ABL90 FLEX PLUS
B Predicate 510(k) Number(s):
K160153
C Comparison with Predicate(s):
Device & Predicate
K240998 K160153
Device(s):
ABL90 FLEX PLUS
Device Trade Name ABL90 FLEX PLUS
System
General Device
Characteristic Similarities
The ABL90 FLEX
Indications For Use Same
PLUS System is an in
K240998 - Page 4 of 20

[Table 1 on page 4]
	Device & Predicate		K240998	K160153
	Device(s):			
Device Trade Name			ABL90 FLEX PLUS
System	ABL90 FLEX PLUS
	General Device			
	Characteristic Similarities			
Indications For Use			The ABL90 FLEX
PLUS System is an in	Same

--- Page 5 ---
Device & Predicate
K240998 K160153
Device(s):
vitro diagnostic,
portable, automated
analyzer that
quantitatively measures
pH, blood gas (pO2),
Oximetry (sO2, ctHb,
FO2Hb, FCOHb,
FMetHb, and FHHb), in
heparinized arterial and
venous whole blood.
The ABL90 FLEX
PLUS System is
intended for use by
trained technologists,
Intended Use and
nurses, physicians, and Same
Environment
therapists in a
laboratory environment,
near patient, or point-
of-care setting.
Prescription/OTC
Prescription Use Same
Use
Sample Volume 65uL Same
Sensor cassette and
Consumables Same
Solution pack
General Device
Characteristic Differences
Potentiometry, optical,
Potentiometry, optical,
Test Principles spectrophotometry, and
and spectrophotometry
amperometry
VI Standards/Guidance Documents Referenced:
Clinical and Laboratory Standards Institute (CLSI) EP05-A3 – Evaluation of Precision of
Quantitative Measurement Procedures
CLSI EP09c 3rd Edition – Measurement Procedure Comparison and Bias Estimation Using
Patient Samples
CLSI EP17-A2 2nd Edition – Evaluation of Detection Capability for Clinical Laboratory
Measurement Procedures; Approved Guideline
CLSI EP06-2nd Edition – Evaluation of Linearity of Quantitative Measurement Procedures.
CLSI EP07-3rd Edition – Interference Testing in Clinical Chemistry
CLSI EP37 1st Edition – Supplemental Tables for Interference Testing in Clinical Chemistry
K240998 - Page 5 of 20

[Table 1 on page 5]
	Device & Predicate		K240998	K160153
	Device(s):			
			vitro diagnostic,
portable, automated
analyzer that
quantitatively measures
pH, blood gas (pO2),
Oximetry (sO2, ctHb,
FO2Hb, FCOHb,
FMetHb, and FHHb), in
heparinized arterial and
venous whole blood.	
Intended Use and
Environment			The ABL90 FLEX
PLUS System is
intended for use by
trained technologists,
nurses, physicians, and
therapists in a
laboratory environment,
near patient, or point-
of-care setting.	Same
Prescription/OTC
Use			Prescription Use	Same
Sample Volume			65uL	Same
Consumables			Sensor cassette and
Solution pack	Same
	General Device			
	Characteristic Differences			
Test Principles			Potentiometry, optical,
and spectrophotometry	Potentiometry, optical,
spectrophotometry, and
amperometry

--- Page 6 ---
CLSI EP39 1st Edition – A Hierarchical Approach to Selecting Surrogate Samples
for the Evaluation of In Vitro Medical Laboratory Tests
VII Performance Characteristics (if/when applicable):
A Analytical Performance:
1. Precision/Reproducibility:
Point of care precision (aqueous control material):
A multi-day precision study was performed at three point of care (POC) sites using four
concentrations of aqueous control solutions. At each site, each level was tested as two
replicates per run, two runs per day, for twenty days. At least three POC operators were
included at each site. Repeatability, within-laboratory precision, and reproducibility results
are reported below:
Within Lab
Parameter QC Repeatability Reproducibility
N Mean Precision
(units) Level
SD CV% SD CV% SD CV%
L1 243* 7.066 0.0034 0 0 0 0.0038 0.1
L2 244 7.39 0.0018 0 0 0 0.0019 0
pH
L3 244 7.582 0.0018 0 0 0 0.0018 0
L4 244 6.784 0.0037 0.1 0 0.1 0.0041 0.1
L1 243* 154.3 1.91 1.2 2.9 1.9 3.13 2
pO2 L2 244 100.3 1.13 1.1 2 2 2.01 2
(mmHg) L3 244 56.1 0.95 1.7 1.3 2.4 1.33 2.4
L4 244 310 3 1 5.5 1.8 6.95 2.2
L1 243* 50 0.01 0 0 0 0.06 0.1
L2 244 96.9 0.03 0 0.1 0.1 0.12 0.1
sO2 (%)
L3 244 70 0.01 0 0 0 0.03 0
L4 244 5 0.01 0.2 0 0.5 0.03 0.5
L1 243* 8.1 0.02 0.2 0 0.4 0.04 0.6
ctHb L2 244 12.9 0.03 0.2 0 0.3 0.06 0.5
(g/dL) L3 244 19.3 0.03 0.2 0.1 0.3 0.09 0.5
L4 244 2.7 0.01 0.4 0 0.6 0.02 0.6
L1 243* 44.6 0.03 0.1 0.1 0.1 0.05 0.1
FO2Hb L2 244 92.2 0.04 0 0.1 0.1 0.06 0.1
(%) L3 244 49 0.02 0.1 0.1 0.1 0.05 0.1
L4 244 3.5 0.01 0.3 0 0.7 0.03 0.8
L1 243* 5.9 0.03 0.6 0.1 1 0.11 1.8
FCOHb L2 244 2.8 0.03 1.1 0.1 2.9 0.13 4.7
(%) L3 244 20 0.02 0.1 0.1 0.3 0.05 0.3
L4 244 10.1 0.02 0.2 0 0.3 0.06 0.6
K240998 - Page 6 of 20

[Table 1 on page 6]
Parameter
(units)	QC
Level	N	Mean	Repeatability							Within Lab					Reproducibility					
											Precision										
					SD			CV%			SD			CV%			SD			CV%	
pH	L1	243*	7.066	0.0034			0			0			0			0.0038			0.1		
	L2	244	7.39	0.0018			0			0			0			0.0019			0		
	L3	244	7.582	0.0018			0			0			0			0.0018			0		
	L4	244	6.784	0.0037			0.1			0			0.1			0.0041			0.1		
pO2
(mmHg)	L1	243*	154.3	1.91			1.2			2.9			1.9			3.13			2		
	L2	244	100.3	1.13			1.1			2			2			2.01			2		
	L3	244	56.1	0.95			1.7			1.3			2.4			1.33			2.4		
	L4	244	310	3			1			5.5			1.8			6.95			2.2		
sO2 (%)	L1	243*	50	0.01			0			0			0			0.06			0.1		
	L2	244	96.9	0.03			0			0.1			0.1			0.12			0.1		
	L3	244	70	0.01			0			0			0			0.03			0		
	L4	244	5	0.01			0.2			0			0.5			0.03			0.5		
ctHb
(g/dL)	L1	243*	8.1	0.02			0.2			0			0.4			0.04			0.6		
	L2	244	12.9	0.03			0.2			0			0.3			0.06			0.5		
	L3	244	19.3	0.03			0.2			0.1			0.3			0.09			0.5		
	L4	244	2.7	0.01			0.4			0			0.6			0.02			0.6		
FO2Hb
(%)	L1	243*	44.6	0.03			0.1			0.1			0.1			0.05			0.1		
	L2	244	92.2	0.04			0			0.1			0.1			0.06			0.1		
	L3	244	49	0.02			0.1			0.1			0.1			0.05			0.1		
	L4	244	3.5	0.01			0.3			0			0.7			0.03			0.8		
FCOHb
(%)	L1	243*	5.9	0.03			0.6			0.1			1			0.11			1.8		
	L2	244	2.8	0.03			1.1			0.1			2.9			0.13			4.7		
	L3	244	20	0.02			0.1			0.1			0.3			0.05			0.3		
	L4	244	10.1	0.02			0.2			0			0.3			0.06			0.6		

[Table 2 on page 6]
Parameter
(units)

[Table 3 on page 6]
QC
Level

--- Page 7 ---
Within Lab
Parameter QC Repeatability Reproducibility
N Mean Precision
(units) Level
SD CV% SD CV% SD CV%
L1 243* 5 0.01 0.3 0 0.6 0.05 0.9
FMetHb L2 244 2 0.02 0.8 0 2.1 0.05 2.3
(%) L3 244 10 0.02 0.2 0 0.2 0.03 0.3
L4 244 20.1 0.04 0.2 0.1 0.3 0.09 0.4
L1 243* 44.6 0.03 0.1 0.1 0.1 0.13 0.3
FHHb L2 244 3 0.02 0.7 0.1 2 0.09 3.2
(%) L3 244 21 0.01 0.1 0 0.1 0.03 0.1
L4 244 66.3 0.05 0.1 0.07 0.1 0.13 0.2
*One L1 sample replicate was excluded due to insufficient sample being loaded onto the
instrument.
Point of Care precision (Whole Blood):
A multi-day precision study was performed at three sites by at least three POC operators at
each site, using balanced heparinized whole blood targeted to levels within the reportable
range of each analyte. The whole blood precision was assessed using the duplicate test
results collected across multiple point of care sites using both the S65 and SP65 sampling
modes. Samples were grouped into subintervals based on their mean values. The results are
summarized below.
K240998 - Page 7 of 20

[Table 1 on page 7]
Parameter
(units)	QC
Level	N	Mean	Repeatability							Within Lab					Reproducibility					
											Precision										
					SD			CV%			SD			CV%			SD			CV%	
FMetHb
(%)	L1	243*	5	0.01			0.3			0			0.6			0.05			0.9		
	L2	244	2	0.02			0.8			0			2.1			0.05			2.3		
	L3	244	10	0.02			0.2			0			0.2			0.03			0.3		
	L4	244	20.1	0.04			0.2			0.1			0.3			0.09			0.4		
FHHb
(%)	L1	243*	44.6	0.03			0.1			0.1			0.1			0.13			0.3		
	L2	244	3	0.02			0.7			0.1			2			0.09			3.2		
	L3	244	21	0.01			0.1			0			0.1			0.03			0.1		
	L4	244	66.3	0.05			0.1			0.07			0.1			0.13			0.2		

[Table 2 on page 7]
Parameter
(units)

[Table 3 on page 7]
QC
Level

--- Page 8 ---
Parameter Repeatability
N Test interval Mean
(unit) SD CV%
S65 Mode
18 6.9 - <7.2 7.141 0.003 0.04
38 7.2 - <7.35 7.298 0.002 0.03
pH
130 7.35 - <7.45 7.405 0.003 0.04
60 7.45 - <7.55 7.480 0.003 0.04
48 30.1 - <60 41.904 0.252 0.60
114 60 - <83 73.424 1.031 1.40
pO2 (mmHg)
42 83 - <108 90.771 1.198 1.32
18 108 - <150 124.50 0.850 0.68
24 6.750 - 7.950 7.533 0.082 1.08
ctHb (g/dL) 184 8.050 -13.250 10.784 0.083 0.77
34 13.550 -17.150 14.941 0.077 0.51
34 3.3 - <80 64.221 0.890 1.39
sO2 (%) 36 80 - <94 91.767 0.147 0.16
158 94 - <100 96.934 0.177 0.18
34 3.3 - <80 63.215 0.918 1.45
FO2Hb (%) 64 80 - <94 91.677 0.146 0.16
130 94 - <98.5 96.083 0.165 0.17
62 0.5 - <1.5 0.797 0.070 8.73
FMetHb (%) 4 1.5 - <20 1.825 0.050 2.74
12 20 - <50 40.667 0.058 0.14
162 1 - <5 1.323 0.059 4.48
FCOHb (%) 6 5 - <35 32.733 0.058 0.18
12 35 - <50 39.492 0.065 0.16
112 1.5 - <5 2.876 0.198 6.87
FHHb (%) 34 10 - <40 30.297 0.860 2.84
4 40 - <70 53.350 0.158 0.30
SP65 Mode
18 6.9 - <7.2 7.135 0.003 0.05
33 7.2 - <7.35 7.302 0.001 0.02
pH (pH unit)
133 7.35 - <7.45 7.402 0.002 0.02
60 7.45 - <7.55 7.482 0.001 0.01
49 30.1 - <60 42.322 0.197 0.47
96 60 - <83 73.383 0.842 1.15
pO2 (mmHg)
55 83 - <108 91.136 1.343 1.47
20 108 - <150 121.85 1.204 0.99
16 6.5 - <8 7.456 0.066 0.89
ctHb (g/dL) 188 8 - <13.5 10.598 0.091 0.86
36 13.5 - <17.5 14.931 0.069 0.46
K240998 - Page 8 of 20

[Table 1 on page 8]
	Parameter		N	Test interval	Mean		Repeatability				
	(unit)						SD			CV%	
S65 Mode											
pH			18	6.9 - <7.2	7.141	0.003			0.04		
			38	7.2 - <7.35	7.298	0.002			0.03		
			130	7.35 - <7.45	7.405	0.003			0.04		
			60	7.45 - <7.55	7.480	0.003			0.04		
pO2 (mmHg)			48	30.1 - <60	41.904	0.252			0.60		
			114	60 - <83	73.424	1.031			1.40		
			42	83 - <108	90.771	1.198			1.32		
			18	108 - <150	124.50	0.850			0.68		
ctHb (g/dL)			24	6.750 - 7.950	7.533	0.082			1.08		
			184	8.050 -13.250	10.784	0.083			0.77		
			34	13.550 -17.150	14.941	0.077			0.51		
sO2 (%)			34	3.3 - <80	64.221	0.890			1.39		
			36	80 - <94	91.767	0.147			0.16		
			158	94 - <100	96.934	0.177			0.18		
FO2Hb (%)			34	3.3 - <80	63.215	0.918			1.45		
			64	80 - <94	91.677	0.146			0.16		
			130	94 - <98.5	96.083	0.165			0.17		
FMetHb (%)			62	0.5 - <1.5	0.797	0.070			8.73		
			4	1.5 - <20	1.825	0.050			2.74		
			12	20 - <50	40.667	0.058			0.14		
FCOHb (%)			162	1 - <5	1.323	0.059			4.48		
			6	5 - <35	32.733	0.058			0.18		
			12	35 - <50	39.492	0.065			0.16		
FHHb (%)			112	1.5 - <5	2.876	0.198			6.87		
			34	10 - <40	30.297	0.860			2.84		
			4	40 - <70	53.350	0.158			0.30		
SP65 Mode											
pH (pH unit)			18	6.9 - <7.2	7.135	0.003			0.05		
			33	7.2 - <7.35	7.302	0.001			0.02		
			133	7.35 - <7.45	7.402	0.002			0.02		
			60	7.45 - <7.55	7.482	0.001			0.01		
pO2 (mmHg)			49	30.1 - <60	42.322	0.197			0.47		
			96	60 - <83	73.383	0.842			1.15		
			55	83 - <108	91.136	1.343			1.47		
			20	108 - <150	121.85	1.204			0.99		
ctHb (g/dL)			16	6.5 - <8	7.456	0.066			0.89		
			188	8 - <13.5	10.598	0.091			0.86		
			36	13.5 - <17.5	14.931	0.069			0.46		

--- Page 9 ---
Parameter Repeatability
N Test interval Mean
(unit) SD CV%
36 3.3 - <80 62.644 0.282 0.45
sO2 (%) 33 80 - <94 91.858 0.203 0.22
155 94 - <100 97.126 0.234 0.24
36 3.3 - <80 61.633 0.306 0.50
FO2Hb (%) 59 80 - <94 91.763 0.181 0.20
131 94 - <98.5 96.327 0.185 0.19
62 0.5 - <1.5 0.777 0.070 9.04
FMetHb (%) 4 1.5 - <20 1.825 0.050 2.74
12 20 - <50 40.575 0.050 0.12
156 1 - <5 1.317 0.063 4.78
FCOHb (%) 6 5 - <35 32.683 0.041 0.12
12 35 - <50 40.367 0.058 0.14
109 1.5 - <5 3.045 0.248 8.14
FHHb (%) 30 10 - <40 31.060 0.292 0.94
8 40 - <70 51.963 0.137 0.26
2. Linearity:
Linearity testing was conducted in general accordance with CLSI EP06-A2. The linearity of
the ABL90 FLEX PLUS System test for pH, pO2, sO2, ctHB, FO2Hb, FCOHb, FMetHb,
and FHHb was evaluated by preparing balanced heparinized venous whole blood samples.
To achieve target concentrations, samples for pH were adjusted with either HCL or NaOH,
samples for ctHB were adjusted for with the addition of plasma and erythrocytes, and
samples for sO2, FO2Hb, FHHb, FCOHb, and pO2 were prepared via tonometry. At least 10
replicates were run for each level.
Parameter Reportable
Tested Range Slope Intercept R2
(units) Range
6.818 –
pH 6.605 – 7.997 1.047 -0.342 1.000
7.797
30.1 –
pO2 (mmHg) 6.110 – 565.600 0.994 -0.543 1.000
488
3.3 –
sO2 (%) 2.180 – 100.220 1.005 -0.324 1.000
100.000
0.1 –
ctHb (g/dL) 0.068 – 27.600 1.024 -0.049 1.000
24.000
3.3 –
FO2Hb (%) 2.180 – 98.960 1.014 -0.492 1.000
98.500
1.00 –
FCOHb (%) 0.540 – 95.790 1.008 -0.493 1.000
92.200
FMetHb (%) 0.5 – 91 0.490 – 95.610 1.033 0.068 1.000
1.5 –
FHHb (%) 0.530 – 98.370 0.997 0.363 1.000
98.300
K240998 - Page 9 of 20

[Table 1 on page 9]
	Parameter		N	Test interval	Mean		Repeatability				
	(unit)						SD			CV%	
sO2 (%)			36	3.3 - <80	62.644	0.282			0.45		
			33	80 - <94	91.858	0.203			0.22		
			155	94 - <100	97.126	0.234			0.24		
FO2Hb (%)			36	3.3 - <80	61.633	0.306			0.50		
			59	80 - <94	91.763	0.181			0.20		
			131	94 - <98.5	96.327	0.185			0.19		
FMetHb (%)			62	0.5 - <1.5	0.777	0.070			9.04		
			4	1.5 - <20	1.825	0.050			2.74		
			12	20 - <50	40.575	0.050			0.12		
FCOHb (%)			156	1 - <5	1.317	0.063			4.78		
			6	5 - <35	32.683	0.041			0.12		
			12	35 - <50	40.367	0.058			0.14		
FHHb (%)			109	1.5 - <5	3.045	0.248			8.14		
			30	10 - <40	31.060	0.292			0.94		
			8	40 - <70	51.963	0.137			0.26		

[Table 2 on page 9]
	Parameter			Reportable		Tested Range	Slope	Intercept	R2
	(units)			Range					
pH			6.818 –
7.797			6.605 – 7.997	1.047	-0.342	1.000
pO2 (mmHg)			30.1 –
488			6.110 – 565.600	0.994	-0.543	1.000
sO2 (%)			3.3 –
100.000			2.180 – 100.220	1.005	-0.324	1.000
ctHb (g/dL)			0.1 –
24.000			0.068 – 27.600	1.024	-0.049	1.000
FO2Hb (%)			3.3 –
98.500			2.180 – 98.960	1.014	-0.492	1.000
FCOHb (%)			1.00 –
92.200			0.540 – 95.790	1.008	-0.493	1.000
FMetHb (%)			0.5 – 91			0.490 – 95.610	1.033	0.068	1.000
FHHb (%)			1.5 –
98.300			0.530 – 98.370	0.997	0.363	1.000

--- Page 10 ---
3. Analytical Specificity/Interference:
Interference testing was performed according to CLSI EP07-ED3 and CLSI EP37-ED1 and
consisted of two parts: paired-difference testing and dose-response experiments.
a. The paired-difference testing was conducted on all potential interferents. Matched
samples were tested, one with no interferent and the other with the interferent. If
no interference was found, no further testing was performed.
b. The dose-response experiment was only conducted on interferents found to have
an effect via the paired-difference testing. This was carried out to determine the
concentration at which clinically significant interference occurred.
Freshly drawn heparinized adult venous whole blood was used as starting material for all
interference studies. Interference testing was conducted at two levels (i.e., low and high) for
pH, pO2, sO2, ctHB, FO2Hb, FCOHb, FMetHb, and FHHb. The following tables list the
concentrations of each substance at which no significant interference was found.
Highest concentration tested at which no significant interference is observed
Potential interferent for parameter pH Concentration
Bilirubin, conjugated 40 mg/dL
Bilirubin, unconjugated 40 mg/dL
Biotin 3510ng/mL
Hemolysis 20%
Intralipid 2000 mg/dL
Propofol 4.8 mg/dL
Potassium (‐chloride) 17 mmol/L
Sodium (‐chloride) 190 mmol/L
Calcium (‐chloride) 22 mg/dL
Potential interferent for parameter pO2 Concentration
Bilirubin, conjugated 40 mg/dL
Bilirubin, unconjugated 40 mg/dL
Biotin 3510ng/mL
Fluorescein 40 mg/dL
Hemolysis 20%
Intralipid 2000 mg/dL
Propofol 4.8 mg/dL
Potential interferent for parameter ctHb Concentration
Betacarotene 0.20 mg/dL
Bilirubin, conjugated 40 mg/dL
Bilirubin, unconjugated 40 mg/dL
Biotin 3510ng/mL
Cardio green (indocyanine green) 3 mg/dL
Evans Blue 0.50 mg/dL
Hemolysis 20%
Patent blue V (sulphan Blue) 1 mg/dL
pH low 6.8
pH high 8.0
Propofol 4.8 mg/dL
K240998 - Page 10 of 20

[Table 1 on page 10]
	Potential interferent for parameter pH			Concentration	
Bilirubin, conjugated			40 mg/dL		
Bilirubin, unconjugated			40 mg/dL		
Biotin			3510ng/mL		
Hemolysis			20%		
Intralipid			2000 mg/dL		
Propofol			4.8 mg/dL		
Potassium (‐chloride)			17 mmol/L		
Sodium (‐chloride)			190 mmol/L		
Calcium (‐chloride)			22 mg/dL		
	Potential interferent for parameter pO2			Concentration	
Bilirubin, conjugated			40 mg/dL		
Bilirubin, unconjugated			40 mg/dL		
Biotin			3510ng/mL		
Fluorescein			40 mg/dL		
Hemolysis			20%		
Intralipid			2000 mg/dL		
Propofol			4.8 mg/dL		
	Potential interferent for parameter ctHb			Concentration	
Betacarotene			0.20 mg/dL		
Bilirubin, conjugated			40 mg/dL		
Bilirubin, unconjugated			40 mg/dL		
Biotin			3510ng/mL		
Cardio green (indocyanine green)			3 mg/dL		
Evans Blue			0.50 mg/dL		
Hemolysis			20%		
Patent blue V (sulphan Blue)			1 mg/dL		
pH low			6.8		
pH high			8.0		
Propofol			4.8 mg/dL		

--- Page 11 ---
Rifampicin 6.4 mg/dL
Sodium nitroprusside dihydrate 87 µg/L
Triglyceride 1600 mg/dL
Potential interferent for parameter sO2 Concentration
Betacarotene 0.20 mg/dL
Bilirubin, conjugated 40 mg/dL
Bilirubin, unconjugated 40 mg/dL
Biotin 3510ng/mL
Cardio green (indocyanine green) 3 mg/dL
Cyanocobalamin 200 mg/dL
Evans blue 0.50 mg/dL
HbF (fetal hemoglobin) 80%
Hemolysis 20%
Hydroxo‐cobalamine hydrochloride 200 mg/dL
Patent blue V (sulphan Blue) 1 mg/dL
pH low 6.8
pH high 8.0
Potential interferent for parameter FO2Hb Concentration
Betacarotene 0.20 mg/dL
Bilirubin, conjugated 40 mg/dL
Bilirubin, unconjugated 40 mg/dL
Biotin 3510ng/mL
Cardio green (indocyanine green) 3 mg/dL
Evans blue 0.50 mg/dL
HbF (fetal hemoglobin) 80%
Hemolysis 20%
Patent blue V (sulphan Blue) 1 mg/dL
pH low 6.8
pH high 8.0
Potential interferent for parameter FHHb Concentration
Betacarotene 0.20 mg/dL
Biotin 3510ng/mL
Cyanocobalamin 200 mg/dL
Evans blue 0.50 mg/dL
HbF (fetal hemoglobin) 80%
Hemolysis 20%
pH low 6.8
pH high 8.0
Propofol 4.8 mg/dL
Rifampicin 6.4 mg/dL
Potential interferent for parameter FCOHb Concentration
Betacarotene 0.20 mg/dL
Bilirubin, conjugated 40 mg/dL
Bilirubin, unconjugated 40 mg/dL
Biotin 3510ng/mL
Cardio green (indocyanine green) 3 mg/dL
Evans blue 0.50 mg/dL
K240998 - Page 11 of 20

[Table 1 on page 11]
Rifampicin			6.4 mg/dL		
Sodium nitroprusside dihydrate			87 µg/L		
Triglyceride			1600 mg/dL		
	Potential interferent for parameter sO2			Concentration	
Betacarotene			0.20 mg/dL		
Bilirubin, conjugated			40 mg/dL		
Bilirubin, unconjugated			40 mg/dL		
Biotin			3510ng/mL		
Cardio green (indocyanine green)			3 mg/dL		
Cyanocobalamin			200 mg/dL		
Evans blue			0.50 mg/dL		
HbF (fetal hemoglobin)			80%		
Hemolysis			20%		
Hydroxo‐cobalamine hydrochloride			200 mg/dL		
Patent blue V (sulphan Blue)			1 mg/dL		
pH low			6.8		
pH high			8.0		
	Potential interferent for parameter FO2Hb			Concentration	
Betacarotene			0.20 mg/dL		
Bilirubin, conjugated			40 mg/dL		
Bilirubin, unconjugated			40 mg/dL		
Biotin			3510ng/mL		
Cardio green (indocyanine green)			3 mg/dL		
Evans blue			0.50 mg/dL		
HbF (fetal hemoglobin)			80%		
Hemolysis			20%		
Patent blue V (sulphan Blue)			1 mg/dL		
pH low			6.8		
pH high			8.0		
	Potential interferent for parameter FHHb			Concentration	
Betacarotene			0.20 mg/dL		
Biotin			3510ng/mL		
Cyanocobalamin			200 mg/dL		
Evans blue			0.50 mg/dL		
HbF (fetal hemoglobin)			80%		
Hemolysis			20%		
pH low			6.8		
pH high			8.0		
Propofol			4.8 mg/dL		
Rifampicin			6.4 mg/dL		
	Potential interferent for parameter FCOHb			Concentration	
Betacarotene			0.20 mg/dL		
Bilirubin, conjugated			40 mg/dL		
Bilirubin, unconjugated			40 mg/dL		
Biotin			3510ng/mL		
Cardio green (indocyanine green)			3 mg/dL		
Evans blue			0.50 mg/dL		

--- Page 12 ---
HbF (fetal hemoglobin) 80%
Hemolysis 20%
Hydroxo‐cobalamine hydrochloride 200 mg/dL
Patent blue V (sulphan Blue) 1 mg/dL
pH low 6.8
pH high 8.0
Propofol 4.8 mg/dL
Rifampicin 6.4 mg/dL
Sodium nitroprusside dihydrate 87 µg/L
Triglyceride 2000 mg/dL
Potential interferent for parameter FMetH Concentration
Betacarotene 0.20 mg/dL
Bilirubin, conjugated 40 mg/dL
Bilirubin, unconjugated 40 mg/dL
Biotin 3510ng/mL
Evans blue 0.50 mg/dL
HbF (fetal hemoglobin) 80%
Hemolysis 20%
Patent blue V (sulphan Blue) 1 mg/dL
Propofol 4.8 mg/dL
Rifampicin 6.4 mg/dL
Sodium nitroprusside dihydrate 87 µg/L
For those substances that on initial screening were found to interfere, dose response testing was
conducted to establish the concentration limit below which no significant interference is
expected. The results are summarized in the table below:
Highest
Maximum test concentration Impact on Test
Interferent
concentration without Result
interference
ctHb (test level: 10 g/dL)
Cyanocobalamin 200 mg/dL 25 mg/dL 1.44 g/dL *
Fluorescein 40 mg/dL 30 mg/dL -0.72 g/dL *
HiCN 30% 12% 1.2 g/dL *
Hydroxo-cobalamine
200 mg/dL 25 mg/dL 2.66 g/dL *
hydrochloride
1600 mg/dL; No
measurement result Error message
Intralipid 2000 mg/dL
reported above “Turbidity too high.”
1600 mg/dL
Methylene Blue 6 mg/dL 0.38 mg/dL -3.94 g/dL *
SHb 10% 5% -0.86 g/dL **
ctHb (test level: 20 g/dL)
Cyanocobalamin 200 mg/dL 150 mg/dL 0.81 g/dL *
K240998 - Page 12 of 20

[Table 1 on page 12]
HbF (fetal hemoglobin)		80%		
Hemolysis		20%		
Hydroxo‐cobalamine hydrochloride		200 mg/dL		
Patent blue V (sulphan Blue)		1 mg/dL		
pH low		6.8		
pH high		8.0		
Propofol		4.8 mg/dL		
Rifampicin		6.4 mg/dL		
Sodium nitroprusside dihydrate		87 µg/L		
Triglyceride		2000 mg/dL		
	Potential interferent for parameter FMetH		Concentration	
Betacarotene		0.20 mg/dL		
Bilirubin, conjugated		40 mg/dL		
Bilirubin, unconjugated		40 mg/dL		
Biotin		3510ng/mL		
Evans blue		0.50 mg/dL		
HbF (fetal hemoglobin)		80%		
Hemolysis		20%		
Patent blue V (sulphan Blue)		1 mg/dL		
Propofol		4.8 mg/dL		
Rifampicin		6.4 mg/dL		
Sodium nitroprusside dihydrate		87 µg/L		

[Table 2 on page 12]
Interferent		Maximum test
concentration	Highest		Impact on Test
Result	
			concentration			
			without			
			interference			
	ctHb (test level: 10 g/dL)					
Cyanocobalamin		200 mg/dL	25 mg/dL		1.44 g/dL *	
Fluorescein		40 mg/dL	30 mg/dL		-0.72 g/dL *	
HiCN		30%	12%		1.2 g/dL *	
Hydroxo-cobalamine
hydrochloride		200 mg/dL	25 mg/dL		2.66 g/dL *	
Intralipid		2000 mg/dL	1600 mg/dL; No
measurement result
reported above
1600 mg/dL		Error message
“Turbidity too high.”	
Methylene Blue		6 mg/dL	0.38 mg/dL		-3.94 g/dL *	
SHb		10%	5%		-0.86 g/dL **	
	ctHb (test level: 20 g/dL)					
Cyanocobalamin		200 mg/dL	150 mg/dL		0.81 g/dL *	

[Table 3 on page 12]
Maximum test
concentration

[Table 4 on page 12]
Impact on Test
Result

--- Page 13 ---
Fluorescein 40 mg/dL 30 mg/dL -1.95 g/dL *
HiCN 30% 10% 2.4 g/dL *
Hydroxo-cobalamine
200 mg/dL 50 mg/dL 2.66 g/dL *
hydrochloride
1600 mg/dL; No
measurement result Error message
Intralipid 2000 mg/dL
reported above “Turbidity too high.”
1600 mg/dL
Methylene Blue 6 mg/dL 0.75 mg/dL -4.15 g/dL *
SHb 10% 2.5% -1.38 g/dL **
sO2 (test level: 90%)
Fluorescein 40 mg/dL 20 mg/dL -5.62%*
HiCN 30% 6.7% -13%*
1600 mg/dL; No
measurement result Error message
Intralipid 2000 mg/dL
reported above “Turbidity too high.”
1600 mg/dL
Methylene Blue 6 mg/dL 0.75 mg/dL 3.36%*
sO2 (test level: 100%)
Fluorescein 40 mg/dL 10 mg/dL -6.58%*
HiCN 30% 6.3% -14%*
1600 mg/dL; No
measurement result Error message
Intralipid 2000 mg/dL
reported above “Turbidity too high.”
1600 mg/dL
Methylene Blue 6 mg/dL 1.5 mg/dL 4.40%*
FO2Hb (test level: 90%)
Cyanocobalamin 200 mg/dL 150 mg/dL -7.1%*
Fluorescein 40 mg/dL No interference 2.4%*
HiCN 30% 3.1% -37%*
Hydroxo-cobalamine
200 mg/dL 38 mg/dL -14.7%*
hydrochloride
1600 mg/dL; No
measurement result Error message
Intralipid 2000 mg/dL
reported above “Turbidity too high.”
1600 mg/dL
Methylene Blue 6 mg/dL 1.5 mg/dL 27.0%*
SHb 10% 5% -7.9%**
FO2Hb (test level: 100%)
Cyanocobalamin 200 mg/dL 100 mg/dL -8.5%*
Fluorescein 40 mg/dL 20 mg/dL 9.16%*
HiCN 30% 3.2% -40%*
Hydroxo-cobalamine
200 mg/dL 38 mg/dL -16.7%*
hydrochloride
K240998 - Page 13 of 20

[Table 1 on page 13]
Fluorescein		40 mg/dL	30 mg/dL	-1.95 g/dL *	
HiCN		30%	10%	2.4 g/dL *	
Hydroxo-cobalamine
hydrochloride		200 mg/dL	50 mg/dL	2.66 g/dL *	
Intralipid		2000 mg/dL	1600 mg/dL; No
measurement result
reported above
1600 mg/dL	Error message
“Turbidity too high.”	
Methylene Blue		6 mg/dL	0.75 mg/dL	-4.15 g/dL *	
SHb		10%	2.5%	-1.38 g/dL **	
	sO2 (test level: 90%)				
Fluorescein		40 mg/dL	20 mg/dL	-5.62%*	
HiCN		30%	6.7%	-13%*	
Intralipid		2000 mg/dL	1600 mg/dL; No
measurement result
reported above
1600 mg/dL	Error message
“Turbidity too high.”	
Methylene Blue		6 mg/dL	0.75 mg/dL	3.36%*	
	sO2 (test level: 100%)				
Fluorescein		40 mg/dL	10 mg/dL	-6.58%*	
HiCN		30%	6.3%	-14%*	
Intralipid		2000 mg/dL	1600 mg/dL; No
measurement result
reported above
1600 mg/dL	Error message
“Turbidity too high.”	
Methylene Blue		6 mg/dL	1.5 mg/dL	4.40%*	
	FO2Hb (test level: 90%)				
Cyanocobalamin		200 mg/dL	150 mg/dL	-7.1%*	
Fluorescein		40 mg/dL	No interference	2.4%*	
HiCN		30%	3.1%	-37%*	
Hydroxo-cobalamine
hydrochloride		200 mg/dL	38 mg/dL	-14.7%*	
Intralipid		2000 mg/dL	1600 mg/dL; No
measurement result
reported above
1600 mg/dL	Error message
“Turbidity too high.”	
Methylene Blue		6 mg/dL	1.5 mg/dL	27.0%*	
SHb		10%	5%	-7.9%**	
	FO2Hb (test level: 100%)				
Cyanocobalamin		200 mg/dL	100 mg/dL	-8.5%*	
Fluorescein		40 mg/dL	20 mg/dL	9.16%*	
HiCN		30%	3.2%	-40%*	
Hydroxo-cobalamine
hydrochloride		200 mg/dL	38 mg/dL	-16.7%*	

--- Page 14 ---
1600 mg/dL; No
measurement result Error message
Intralipid 2000 mg/dL
reported above “Turbidity too high.”
1600 mg/dL
Methylene Blue 6 mg/dL 1.1 mg/dL 34.3%*
SHb 10% 5% -14.6%**
FHHb (test level: 2.4%)
0.684 mmol/L
Bilirubin (unconj) No interference -0.26%
40 mg/dL
0.475 mmol/L
Bilirubin (conj) No interference -0.44%
40 mg/dL
Cardio green (indocyanine
3 mg/dL 0.75 mg/dL -1.16%
green)
Fluorescein 40 mg/dL 10 mg/dL 7.68%*
HiCN 30% 3.6% 8.9%*
Hydroxo-cobalamine
200 mg/dL No interference -0.88%*
hydrochloride
800 mg/dL; No
measurement result Error message
Intralipid 2000 mg/dL
reported “Turbidity too high.”
above 1600 mg/dL.
Methylene Blue 6 mg/dL 0.38 mg/dL -4.44%*
Patent Blue V (sulphan
1 mg/dL 0.06 mg/dL -1.78%
Blue)
SHb 10% 0.5% 34.5%**
Sodium nitroprusside
0.87 mg/dL No interference -0.08%
dihydrate
Triglyceride 1600 mg/dL 800 mg/dL 1.42%
FHHb (test level: 10%)
0.684 mmol/L 0.17 mmol/L
Bilirubin (unconj) -0.82%*
40 mg/dL 10 mg/dL
0.475 mmol/L 0.06 mmol/L
Bilirubin (conj) -0.88%*
40 mg/dL 5 mg/dL
Cardio green (indocyanine
3 mg/dL 0.75 mg/dL -2.0%
green)
Fluorescein 40 mg/dL 5 mg/dL 7.34%*
HiCN 30% 4.5% 6.1%*
Hydroxo-cobalamine
200 mg/dL 150 mg/dL -1.26%*
hydrochloride
1200 mg/dL; No
measurement result Error message
Intralipid 2000 mg/dL
reported above “Turbidity too high.”
1600 mg/dL.
Methylene Blue 6 mg/dL 0.38 mg/dL -1.58%*
Patent Blue V (sulphan
1 mg/dL 0.006 mg/dL -0.98%
Blue)
K240998 - Page 14 of 20

[Table 1 on page 14]
Intralipid		2000 mg/dL	1600 mg/dL; No
measurement result
reported above
1600 mg/dL	Error message
“Turbidity too high.”	
Methylene Blue		6 mg/dL	1.1 mg/dL	34.3%*	
SHb		10%	5%	-14.6%**	
	FHHb (test level: 2.4%)				
Bilirubin (unconj)		0.684 mmol/L
40 mg/dL	No interference	-0.26%	
Bilirubin (conj)		0.475 mmol/L
40 mg/dL	No interference	-0.44%	
Cardio green (indocyanine
green)		3 mg/dL	0.75 mg/dL	-1.16%	
Fluorescein		40 mg/dL	10 mg/dL	7.68%*	
HiCN		30%	3.6%	8.9%*	
Hydroxo-cobalamine
hydrochloride		200 mg/dL	No interference	-0.88%*	
Intralipid		2000 mg/dL	800 mg/dL; No
measurement result
reported
above 1600 mg/dL.	Error message
“Turbidity too high.”	
Methylene Blue		6 mg/dL	0.38 mg/dL	-4.44%*	
Patent Blue V (sulphan
Blue)		1 mg/dL	0.06 mg/dL	-1.78%	
SHb		10%	0.5%	34.5%**	
Sodium nitroprusside
dihydrate		0.87 mg/dL	No interference	-0.08%	
Triglyceride		1600 mg/dL	800 mg/dL	1.42%	
	FHHb (test level: 10%)				
Bilirubin (unconj)		0.684 mmol/L
40 mg/dL	0.17 mmol/L
10 mg/dL	-0.82%*	
Bilirubin (conj)		0.475 mmol/L
40 mg/dL	0.06 mmol/L
5 mg/dL	-0.88%*	
Cardio green (indocyanine
green)		3 mg/dL	0.75 mg/dL	-2.0%	
Fluorescein		40 mg/dL	5 mg/dL	7.34%*	
HiCN		30%	4.5%	6.1%*	
Hydroxo-cobalamine
hydrochloride		200 mg/dL	150 mg/dL	-1.26%*	
Intralipid		2000 mg/dL	1200 mg/dL; No
measurement result
reported above
1600 mg/dL.	Error message
“Turbidity too high.”	
Methylene Blue		6 mg/dL	0.38 mg/dL	-1.58%*	
Patent Blue V (sulphan
Blue)		1 mg/dL	0.006 mg/dL	-0.98%	

--- Page 15 ---
SHb 10% 2.5% 17.2%**
Sodium nitroprusside
0.87 mg/dL 0.22 mg/dL -0.52%
dihydrate
Triglyceride 1600 mg/dL 1200 mg/dL 1.20%
FCOHb (test level: 1%)
Cyanocobalamin 200 mg/dL 50 mg/dL 1.7%*
Fluorescein 40 mg/dL 2.5 mg/dL -10.64%*
HiCN 30% 3.4% 6.3%*
1600 mg/dL; No
measurement result Error message
Intralipid 2000 mg/dL
reported above “Turbidity too high.”
1600 mg/dL
Methylene Blue 6 mg/dL No interference 0.64%*
SHb 10% 1.25% 1.08%**
FCOHb (test level: 10%)
Cyanocobalamin 200 mg/dL 100 mg/dL 1.1%*
Fluorescein 40 mg/dL 3.75 mg/dL -10.84%*
HiCN 30% 9.6% 2.9%*
1600 mg/d;L No
measurement result Error message
Intralipid 2000 mg/dL
reported above “Turbidity too high.”
1600 mg/dL
Methylene Blue 6 mg/dL 1.5 mg/dL 1.88%*
SHb 10% 2.5% 1.58%**
FMetHb (test level: 1.0%)
Cardio green (indocyanine
3 mg/dL 1.5 mg/dL -1.48%
green)
Cyanocobalamin 200 mg/dL 12.5 mg/dL 5.44%*
Fluorescein 40 mg/dL 30 mg/dL -9.88%*
HiCN 30% 1.1% 24%*
Hydroxo-cobalamine
200 mg/dL 8 mg/dL 13.1%*
hydrochloride
1200 mg/dL
No measurement Error message
Intralipid 2000 mg/dL
result reported “Turbidity too high.”
above 1600 mg/dL
Methylene Blue 6 mg/dL 0.08 mg/dL -33%*
pH low 6.8 No interference 0.96%
pH high 8.0 No interference -0.76%
SHb 10% No interference -0.7%**
Triglyceride 1600 mg/dL 1200 mg/dL 0.96%
*At the concentrations that might cause interference, the instrument reports an error message
when these substances are detected with error message: “OXI spectrum mismatch”.
K240998 - Page 15 of 20

[Table 1 on page 15]
SHb		10%	2.5%	17.2%**	
Sodium nitroprusside
dihydrate		0.87 mg/dL	0.22 mg/dL	-0.52%	
Triglyceride		1600 mg/dL	1200 mg/dL	1.20%	
	FCOHb (test level: 1%)				
Cyanocobalamin		200 mg/dL	50 mg/dL	1.7%*	
Fluorescein		40 mg/dL	2.5 mg/dL	-10.64%*	
HiCN		30%	3.4%	6.3%*	
Intralipid		2000 mg/dL	1600 mg/dL; No
measurement result
reported above
1600 mg/dL	Error message
“Turbidity too high.”	
Methylene Blue		6 mg/dL	No interference	0.64%*	
SHb		10%	1.25%	1.08%**	
	FCOHb (test level: 10%)				
Cyanocobalamin		200 mg/dL	100 mg/dL	1.1%*	
Fluorescein		40 mg/dL	3.75 mg/dL	-10.84%*	
HiCN		30%	9.6%	2.9%*	
Intralipid		2000 mg/dL	1600 mg/d;L No
measurement result
reported above
1600 mg/dL	Error message
“Turbidity too high.”	
Methylene Blue		6 mg/dL	1.5 mg/dL	1.88%*	
SHb		10%	2.5%	1.58%**	
	FMetHb (test level: 1.0%)				
Cardio green (indocyanine
green)		3 mg/dL	1.5 mg/dL	-1.48%	
Cyanocobalamin		200 mg/dL	12.5 mg/dL	5.44%*	
Fluorescein		40 mg/dL	30 mg/dL	-9.88%*	
HiCN		30%	1.1%	24%*	
Hydroxo-cobalamine
hydrochloride		200 mg/dL	8 mg/dL	13.1%*	
Intralipid		2000 mg/dL	1200 mg/dL
No measurement
result reported
above 1600 mg/dL	Error message
“Turbidity too high.”	
Methylene Blue		6 mg/dL	0.08 mg/dL	-33%*	
pH low		6.8	No interference	0.96%	
pH high		8.0	No interference	-0.76%	
SHb		10%	No interference	-0.7%**	
Triglyceride		1600 mg/dL	1200 mg/dL	0.96%	

--- Page 16 ---
** At the concentrations that might cause interference, the result is marked with error message
“Warning, SHb detected.”
The sponsor also included the following limitation in their labeling: “The specificity of
absorbance measurements for tHb, sO2, O2Hb, HHb, COHb, and MetHb is determined by the
optical system – spectrophotometer and algorithm. Substances that change the color of the blood
may absorb light at the same wavelengths as the analyte and give interference on the optical
oximetry measurement. The ABL90 FLEX PLUS System is able to identify some of these
interferents at therapeutic levels in samples, including Fluorescein, HiCN, Methylene Blue, and
Cyanocobalamin and will indicate the “OXI spectrum mismatch” error. However, Patent Blue V
(sulphan Blue), Sodium nitroprusside dihydrate, Cardio green (indocyanine green), and
Hydroxo-cobalamine hydrochloride at therapeutic levels or levels expected in patients can cause
interference in samples not detected and flagged by the ABL90 FLEX PLUS System. See
interferences section for more information.”
4. Assay Reportable Range:
See section A.2 Linearity.
5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):
pH: Traceable to IUPAC pH scale via commercially available certified reference material.
pO2: Traceable to the International System of Units (SI) via commercially available certified
specialty medical gas standards.
ctHb: Traceable to SI using HiCN method (CLSI H15 - Reference and Selected Procedures
for the Quantitative Determination of Hemoglobin in Blood, 3rd Edition.).
6. Detection Limit:
Detection capability testing was conducted in general accordance with CLSI EP17-A2. . To
achieve target concentrations, heparinized venous whole blood samples for pH were adjusted
with either HCL or NaOH, samples for ctHB were adjusted for with the addition of aqueous
buffer solution with or without erythrocytes, samples for FMetHb were adjusted using
isotonic saltwater, and samples for sO2, FO2Hb, FHHb, FCOHb, and pO2 were prepared via
tonometry. Testing was performed on the ABL90 FLEX PLUS System using 3 reagent lots, 9
instruments, over the course of 9 days, using 4 independent samples, with at least 5
replicates/sample, and 60 replicates/reagent lot.
Parameter (units) Reportable Range LoQ results
pH 6.818 – 7.797 6.754
pO2 (mmHg) 30.1 – 488 7.7
sO2 (%) 3.3 – 100.0 1.4
ctHb (g/dL) 0.1 – 24.0 0.09
FO2Hb (%) 3.3 – 98.5 1.4
K240998 - Page 16 of 20

[Table 1 on page 16]
	Parameter (units)			Reportable Range			LoQ results	
pH			6.818 – 7.797			6.754		
pO2 (mmHg)			30.1 – 488			7.7		
sO2 (%)			3.3 – 100.0			1.4		
ctHb (g/dL)			0.1 – 24.0			0.09		
FO2Hb (%)			3.3 – 98.5			1.4		

--- Page 17 ---
Parameter (units) Reportable Range LoQ results
FCOHb (%) 1.00 – 92.2 0.7
FMetHb (%) 0.5 – 91 0.3
FHHb (%) 1.5 – 98.3 1.4
7. Assay Cut-Off:
Not applicable.
8. Accuracy (Instrument):
See section B.1 Method Comparison.
9. Carry-Over:
Not applicable.
B Comparison Studies:
1. Method Comparison with Predicate Device:
Method comparison for arterial and venous whole blood specimens on the ABL90 FLEX
PLUS System was done in general accordance with CLSI EP09c-ED3. Heparinized arterial
and venous whole blood specimens (maximum of 10% contrived) collected across 4 POC
sites, with at least two POC users per site were compared to whole blood specimens tested on
a comparative method. Specifically, each sample was measured once on the candidate device
in one mode (i.e. S65 or SP65) and once on the predicate device in the same mode.
Evaluations were performed per each combination of parameter, blood type, and sampling
mode by linear regression. The regression analysis for these samples are summarized below.
K240998 - Page 17 of 20

[Table 1 on page 17]
	Parameter (units)			Reportable Range			LoQ results	
FCOHb (%)			1.00 – 92.2			0.7		
FMetHb (%)			0.5 – 91			0.3		
FHHb (%)			1.5 – 98.3			1.4		

--- Page 18 ---
Method Comparison Results for S65 mode
Medical
Bias at
Parameter n Intercept Slope R2 decision
MD
point
83.000 0.002
pO2 (mmHg) 401 0.111 0.999 0.999
108.00 -0.031
7.350 -0.003
pH (pH scale) 442 0.018 0.997 0.998
7.450 -0.003
94.000 0.134
sO2 (%) 422 -0.441 1.006 0.999
80.000 0.048
8.400 0.068
tHb (g/dL) 427 0.015 1.006 0.994
17.500 0.126
94.000 0.160
O2Hb (%) 411 -0.492 1.007 0.999
80.000 0.063
10.000 0.005
HHb (%) 338 -0.023 1.003 0.999
5.000 -0.009
10.000 -0.307
COHb (%) 322 -0.332 1.002 0.999
25.000 -0.271
1.500 -0.217
MetHb (%) 49 -0.229 1.008 1.000
20.000 -0.075
Method Comparison Results for SP65 mode
Medical Bias
Parameter n Intercept Slope R2 decision at
point MD
83.000 0.042
pO2 (mmHg) 396 -0.166 1.003 0.999
108.00 0.105
7.350 -0.003
pH (pH scale) 427 0.023 0.996 0.999
7.450 -0.003
94.000 0.212
sO2 (%) 404 -0.395 1.006 0.999
80.000 0.122
8.400 0.076
tHb (g/dL) 412 0.069 1.001 0.996
17.500 0.084
94.000 0.123
O2Hb (%) 393 -0.381 1.005 0.999
80.000 0.048
10.000 -0.089
HHb (%) 318 -0.117 1.003 0.999
5.000 -0.103
10.000 -0.462
COHb (%) 305 -0.394 0.993 0.999
25.000 -0.564
1.500 -0.272
MetHb (%) 42 -0.290 1.012 1.000
20.000 -0.055
K240998 - Page 18 of 20

[Table 1 on page 18]
Parameter	n	Intercept	Slope	R2		Medical		Bias at
MD
						decision		
						point		
pO2 (mmHg)	401	0.111	0.999	0.999	83.000			0.002
					108.00			-0.031
pH (pH scale)	442	0.018	0.997	0.998	7.350			-0.003
					7.450			-0.003
sO2 (%)	422	-0.441	1.006	0.999	94.000			0.134
					80.000			0.048
tHb (g/dL)	427	0.015	1.006	0.994	8.400			0.068
					17.500			0.126
O2Hb (%)	411	-0.492	1.007	0.999	94.000			0.160
					80.000			0.063
HHb (%)	338	-0.023	1.003	0.999	10.000			0.005
					5.000			-0.009
COHb (%)	322	-0.332	1.002	0.999	10.000			-0.307
					25.000			-0.271
MetHb (%)	49	-0.229	1.008	1.000	1.500			-0.217
					20.000			-0.075

[Table 2 on page 18]
Bias at
MD

[Table 3 on page 18]
Parameter	n	Intercept	Slope	R2		Medical			Bias	
						decision			at	
						point			MD	
pO2 (mmHg)	396	-0.166	1.003	0.999	83.000			0.042		
					108.00			0.105		
pH (pH scale)	427	0.023	0.996	0.999	7.350			-0.003		
					7.450			-0.003		
sO2 (%)	404	-0.395	1.006	0.999	94.000			0.212		
					80.000			0.122		
tHb (g/dL)	412	0.069	1.001	0.996	8.400			0.076		
					17.500			0.084		
O2Hb (%)	393	-0.381	1.005	0.999	94.000			0.123		
					80.000			0.048		
HHb (%)	318	-0.117	1.003	0.999	10.000			-0.089		
					5.000			-0.103		
COHb (%)	305	-0.394	0.993	0.999	10.000			-0.462		
					25.000			-0.564		
MetHb (%)	42	-0.290	1.012	1.000	1.500			-0.272		
					20.000			-0.055		

--- Page 19 ---
2. Matrix Comparison:
Not applicable since the only sample types recommended for the candidate device are
balanced heparinized venous and arterial whole blood.
C Clinical Studies:
1. Clinical Sensitivity:
Not applicable.
2. Clinical Specificity:
Not applicable.
3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable):
Not applicable.
D Clinical Cut-Off:
Not applicable.
E Expected Values/Reference Range:
Below are general reference ranges, cited from literature, for a normal, healthy population.
Parameter Reference Range
pH 7.35 – 7.451
pO2 (mmHg) 83 – 10811
sO2 (%)
94-1002
ctHb (g/dL) 13.5 – 17.53 (male) / 12.0 – 16.03 (female) 2
FO2Hb (%) 94 – 982
FCOHb (%)
0-102
FMetHb (%) 0.0 – 1.51
FHHb (%) 0 – 52
1 Tietz NW, Logan NM. Reference ranges, In: Fundamentals of clinical chemistry. 3rd
ed. Philadelphia: WB Saunders Company 1987: 944-75.
2 Burtis CA, Ashwood ER, Bruns DE. Tietz textbook of clinical chemistry and molecular
diagnostics. 5th ed. St. Louis: Saunders Elsevier, 2012.
K240998 - Page 19 of 20

[Table 1 on page 19]
	Parameter			Reference Range	
pH			7.35 – 7.451		
pO2 (mmHg)			83 – 10811		
sO2 (%)			94-1002		
ctHb (g/dL)			13.5 – 17.53 (male) / 12.0 – 16.03 (female) 2		
FO2Hb (%)			94 – 982		
FCOHb (%)			0-102		
FMetHb (%)			0.0 – 1.51		
FHHb (%)			0 – 52		

--- Page 20 ---
VIII Proposed Labeling:
The labeling supports the finding of substantial equivalence for this device.
IX Conclusion:
The submitted information in this premarket notification is complete and does support a
substantial equivalence decision.
K240998 - Page 20 of 20